Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function

Stroke. 2003 Dec;34(12):2975-9. doi: 10.1161/01.STR.0000101914.62066.7B. Epub 2003 Nov 13.

Abstract

Background and purpose: In a model of mechanical focal ischemia, we investigated the involvement of thrombolysis products (TLP) in recombinant tissue plasminogen activator (rtPA)-induced intracerebral complications and the effects on infarct volume and postischemic endothelial function.

Methods: Hemorrhage incidence and severity were evaluated by histomorphometric analysis in male spontaneously hypertensive rats (SHR) subjected to 60-minute intraluminal middle cerebral artery (MCA) occlusion and receiving intravenously 5 hours later either saline, rtPA (3, 10, or 30 mg/kg), or rtPA (10 mg/kg) associated with TLP (rtPA+TLP). In addition, MCA reactivity was assessed in rtPA- or rtPA+TLP-treated SHR versus control Wistar-Kyoto rats or SHR.

Results: No hemorrhage was observed visually in SHR receiving saline. In contrast, rtPA administration induced hemorrhagic complications in infarcted areas in a dose-independent manner. Administration of rtPA+TLP solution, containing a high concentration of plasmin, did not affect hemorrhage incidence but significantly increased hemorrhage severity (8.8+/-2.3 petechiae versus 3.0+/-1.0 petechiae in rtPA group; P<0.001). This increased severity was associated with a significant increase of both infarct volume (182+/-10 versus 144+/-15 mm3 in rtPA group; P<0.01) and postischemic impairment of MCA endothelium-dependent relaxation (9+/-0.5% versus 13+/-1% in rtPA group; P<0.05).

Conclusions: Treatment with rtPA led to intracerebral hemorrhages, in contrast to saline-treated animals, and the presence of TLP increased the severity of these hemorrhages, in parallel with increased infarct volume and worsened endothelial function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cerebral Hemorrhage / chemically induced*
  • Cerebral Hemorrhage / pathology
  • Cerebral Hemorrhage / physiopathology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Fibrin Fibrinogen Degradation Products / pharmacology
  • Fibrinolysin / pharmacology
  • In Vitro Techniques
  • Infarction, Middle Cerebral Artery / drug therapy*
  • Infarction, Middle Cerebral Artery / pathology
  • Male
  • Middle Cerebral Artery / drug effects
  • Middle Cerebral Artery / physiopathology
  • Rats
  • Rats, Inbred SHR
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / pharmacology
  • Survival Rate
  • Thrombolytic Therapy / adverse effects*
  • Tissue Plasminogen Activator / adverse effects*
  • Tissue Plasminogen Activator / pharmacology
  • Vasodilation / drug effects*
  • Vasodilation / physiology
  • Vasomotor System / drug effects
  • Vasomotor System / physiopathology

Substances

  • Fibrin Fibrinogen Degradation Products
  • Recombinant Proteins
  • Tissue Plasminogen Activator
  • Fibrinolysin